Myomo, Inc. MYO

Myomo Inc. shared Q2 earnings call highlights covering revenue, order growth, product demand, and operational updates. Quarterly earnings data and updates can moderately shift short-term stock sentiment and valuation views.

Myomo Inc posted record orders and margin expansion in Q2 2026. Record orders and margin expansion signal stronger revenue growth and profitability ahead for Myomo.

Myomo, Inc. (MYO) released second quarter 2026 financial and operating results. Quarterly results disclosure influences near-term stock valuation and sentiment.

Myomo, Inc. Q1 2026 earnings call summary covers financial results, revenue growth, operational updates, and forward guidance for the neuromuscular robotics company. Q1 earnings summaries provide critical financial data and outlook that can drive significant shifts in stock price and investor confidence.

Myomo, Inc. (MYO) reported first quarter 2026 financial and operating results. Quarterly earnings releases reveal revenue, profitability, and guidance that significantly shape investor sentiment and stock trajectory.

Myomo, Inc. reported first quarter 2025 financial results with revenue of $9.8 million, a 162% increase year-over-year. The company added a record 700 patients to its pipeline, with 1,482 total candidates. Medicare Part B patients accounted for 59% of revenue. Operating loss was $3.5 million, an improvement from $3.9 million in Q1 2024. Gross margin increased to 67.2%. Despite challenges in lead generation, management expects revenue growth to accelerate in the second half of 2025, projecting Q2 revenue between $9.0 million and $9.5 million and full-year revenue of $50 million to $53 million. A conference call is scheduled for today at 4:30 PM Eastern time. Significant revenue growth and patient pipeline expansion indicate a strong strategic position and potential for future performance improvement.

Myomo, Inc. (MYO) reported a first-quarter net loss while surpassing revenue estimates. Q1 revenue beat despite net loss moderately boosts short-term investor sentiment and highlights revenue growth amid profitability hurdles.

Myomo, Inc. (MYO) reported a loss for Q1 but exceeded revenue estimates. The company continues to focus on its innovative products aimed at improving mobility for individuals with neurological conditions. Despite the loss, the revenue performance indicates positive market reception and potential growth opportunities. Exceeding revenue estimates suggests moderate positive influence on financial performance and market sentiment.

Myomo announces its MyoPro orthopedic-myoelectric device is now available at Ottobock Care clinics throughout the U.S., expanding access for patients with neuromuscular disorders via a leading global prosthetics and orthotics provider. Partnership with Ottobock significantly expands MyoPro distribution channels and patient access, boosting revenue potential and market reach.

Myomo, Inc. launches Myomo Mobile App to improve clinical workflow efficiency and boost patient engagement. Mobile app launch enhances product usability, clinical adoption, and patient retention, driving significant growth in Myomo's medtech ecosystem.

Elevance expands coverage for Myomo's MyoPro orthoses across its Medicare Advantage plans, aligning with tech-enabled care initiatives to improve access for upper extremity rehabilitation. Expanded coverage by major payer Elevance significantly increases Myomo's reimbursement opportunities and patient access, driving revenue growth.

Myomo Inc. reported record Q4 2025 revenue driven by strong MyoPro demand, but faced rising expenses from expanded sales force and R&D, with full-year revenue up 34% to $35.4 million and narrowed net loss. Record revenue and 34% annual growth highlight strong market traction for MyoPro, likely boosting investor confidence despite cost pressures.

Myomo, Inc. reported record financial results for Q4 2024, with revenues of $12.1 million, more than double from Q4 2023. The company benefited from Medicare Part B coverage for its MyoPro powered arm brace, allowing access to a previously untapped market. Myomo trained 160 certified prosthetist orthotists and saw significant growth in its O&P distribution channel. The company aims for cash flow breakeven by the end of 2025 and projects 2025 revenues between $50 million and $53 million. Challenges remain with Medicare Advantage denials, but new contracts with health insurance plans are being established. Myomo's international business, particularly in Germany, is also performing well. The expansion of Medicare coverage and significant revenue growth indicate a major strategic shift for Myomo.

Myomo, Inc. (MYO) reported Q4 2024 revenue of $12.1 million, a 154% increase year-over-year, with full-year revenue reaching $32.6 million, up 69%. The company delivered 220 units in Q4, a 106% increase, and achieved a gross margin of 71.4%. Operating expenses rose 60% to $8.9 million, while the net loss narrowed to $300,000. Myomo secured Medicare Part B coverage for its MyoPro arm brace and trained 160 certified prosthetist orthotists. However, challenges remain with Medicare Advantage coverage and rising operating costs. Q1 2025 revenue guidance is set at $9 million to $9.5 million, with full-year guidance of $50 million to $53 million. Significant revenue growth and strategic market expansions indicate a major shift in the company's trajectory.

Myomo, Inc. (MYO) reported fourth quarter and full year 2025 financial and operating results, highlighting key metrics on revenue, profitability, and operational performance. Quarterly and annual financial results directly shape investor sentiment, stock valuation, and future market trajectory.

Myomo, Inc. and Elevance Health have agreed to a contract enabling Myomo's MyoPro orthosis participation in Elevance's multi-state provider network, expanding reimbursement access and patient reach for thousands of members across several states. Contract with major insurer Elevance Health grants Myomo multi-state network access, significantly enhancing reimbursement, patient volume, and revenue trajectory.

Myomo, Inc. (MYO) reported a Q4 net loss but exceeded revenue estimates. Q4 revenue beat despite net loss indicates mixed financial results likely to moderately affect short-term market sentiment and performance.

Myomo, Inc. (MYO) reported strong international growth in its Q3 2025 earnings call, highlighting successful expansion efforts outside the domestic market. Despite challenges in the U.S., the company is optimistic about its future prospects and continues to innovate in its product offerings. Management emphasized the importance of international markets in driving revenue and overall business growth. Significant international growth indicates a major strategic move that could alter the company's trajectory and investor sentiment.

Myomo, Inc. (MYO) reported a loss for Q3 but exceeded revenue estimates. The company continues to focus on its innovative technology for upper limb mobility solutions, which has garnered positive market interest. Despite the loss, the revenue performance indicates potential growth and demand for its products. Exceeding revenue estimates suggests moderate positive momentum, but the reported loss indicates ongoing challenges.

Myomo, Inc. (MYO) reported its financial and operational results for the third quarter of 2025, highlighting key metrics such as revenue growth and product development advancements. The company continues to focus on expanding its market presence and enhancing its offerings in the medical device sector, particularly in the field of rehabilitation technology. Myomo's performance reflects ongoing efforts to innovate and meet the needs of patients requiring assistive devices. Revenue growth and product development may moderately influence Myomo's financial performance and market positioning.

Myomo, Inc. (MYO) will present at the H.C. Wainwright 27th Annual Global Investment Conference, showcasing its advancements in wearable technology for individuals with neuromuscular disorders. The conference is a platform for investors to gain insights into the company's strategies and innovations. Participation in a significant investment conference may enhance investor interest and market visibility.

Myomo, Inc. (MYO) reported a significant revenue increase in Q2 2025, driven by rising demand for its products. However, the company also faced escalating costs, impacting overall profitability. Strategic initiatives were highlighted to address these challenges and enhance market positioning. Management expressed optimism about future growth prospects despite the current cost pressures. The revenue surge combined with rising costs and strategic initiatives indicates a significant impact on future performance and market positioning.

Myomo, Inc. (MYO) reported a loss for Q2 but exceeded revenue estimates. The company continues to focus on its innovative technology for rehabilitation and mobility solutions, which has garnered interest in the healthcare sector. Despite the loss, the revenue performance indicates potential growth opportunities as Myomo expands its market presence. Exceeding revenue estimates suggests moderate growth potential, but the reported loss indicates challenges that may limit overall impact.

Myomo, Inc. (MYO) reported its financial and operating results for the second quarter of 2025, highlighting key metrics such as revenue growth and operational advancements. The company continues to focus on expanding its product offerings and enhancing its market presence, aiming to improve patient outcomes with its innovative technologies. Management provided insights into future strategies and expectations for continued growth in the coming quarters. The reported financial results indicate moderate growth and operational improvements that may influence Myomo's market position.

Myomo, Inc. (NYSE:MYO) aims for $100 million in annual revenue by 2028, with $15 million from international customers and $20 million from its O&P channel. The company highlighted its lead generation capabilities and the untapped market of prospective MyoPro patients during its Investor Day on June 18. Myomo specializes in wearable robotics for patients with neurological disorders and upper limb paralysis. The company's ambitious revenue goal and focus on untapped markets indicate significant strategic moves that could alter its trajectory.

Myomo, Inc. hosted an Investor & Analyst Day event to review its business model and long-term financial goals. Key highlights included recovery in lead generation, untapped patient population, improvements in Medicare Advantage reimbursement, and coverage for over 27 million lives through private payer contracts. Management presented plans for product enhancements, increased manufacturing capacity, and cost reduction projects aimed at improving gross margins. The company aims for $100 million in annual revenue by 2028, with specific targets for international and orthotics and prosthetics channel revenues. The event outlines significant strategic initiatives and financial targets that could substantially influence Myomo's future performance and market position.

Myomo Inc (MYO) reported a 162% revenue increase in Q1 2025, driven by the launch of the MyoPro 2X and strong Medicare Part B penetration. The company added 700 medically qualified candidates to its patient pipeline, with international revenue, particularly from Germany, up 42%. However, challenges included lead generation issues due to Meta's advertising policy changes, delays in authorizations from Medicare Advantage plans, and a 64% rise in operating expenses. The cost per pipeline ad increased by 31%, and the backlog decreased by 9%. Management expressed confidence in pipeline growth and international expansion despite these challenges. The significant revenue surge and strategic innovations indicate a major shift in the company's trajectory.

Myomo, Inc. will host its first Investor & Analyst Day on June 18, 2025, at its new headquarters in Burlington, Mass. The event will showcase the company's innovations, strategic plans, and growth initiatives in wearable medical robotics for individuals with neuromuscular disorders. Attendees will hear from senior management, see product demonstrations, participate in Q&A sessions, and tour the facility. Registration is open for both in-person and virtual attendance. The event is expected to significantly impact Myomo's future performance by highlighting strategic initiatives and innovations that could enhance investor sentiment and market positioning.

Myomo, Inc. has launched the MyoPro 2x, an advanced wearable medical device designed to enhance user independence for individuals with upper-limb paralysis. The MyoPro 2x features a streamlined donning process, improved fit, and updated training materials for clinicians. The development was informed by feedback from over 3000 patients and aims to improve clinical outcomes. Myomo has also initiated a certification process for Orthotic & Prosthetic providers to become MyoPro Centers of Excellence, allowing them to independently treat patients with the new device. CEO Paul R. Gudonis emphasized the importance of user independence in this launch. The launch of the MyoPro 2x represents a significant product innovation that could enhance Myomo's market position and impact patient outcomes.

Myomo, Inc. (MYO) reported a loss for Q4 but exceeded revenue estimates. The company continues to focus on its innovative technology for rehabilitation and mobility solutions, which has garnered interest in the market. Despite the loss, the revenue performance indicates potential growth opportunities ahead. Exceeding revenue estimates suggests moderate positive influence on financial performance and market sentiment.